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The renin system: Variations in man measured
by radioimmunoassay or bioassay
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The renin system: Variations in man measured by radioinimuno-
assay or bioassay. Using a basic incubation procedure followed
by either pressor bioassay or radioimmunoassay of angioten-
sin I, normal values for plasma renin activity (PRA) were
defined in 52 normal subjects over the range of physiological
variation which occurs in relation to changes in sodium balance.
Complete interchangeability of results derived from the two
different methods was achieved by the application of a correc-
tion factor based on the observed lower pressor activity of
angiotensin I. Plasma renin activity exhibits a consistent dynamic
relationship to the daily rate of urinary sodium excretion. The
values ranged from 0.5 to 2.8 ng/ml/hr when sodium excretion
was above 150 mEq/day, from 1.4 to 6.3 ng/ml/hr when sodium
excretion was between 50 and 150 mEq/day, and up to 21 ng/
mi/hr when sodium excretion was below 50 mEq/day. However,
a more precise index derives from using limits inscribed by the
whole curve as a nomogram. Plasma renin substrate measure-
ments did not vary with changes in sodium balance. Its concen-
tration measured by radioimmunoassay ranged from 900 to
2200 ng/ml but intra-individual variation was small. These
values are considerably higher but closer to the true value than
previously reported assays which erroneously compared angio-
tensin I generated during the incubation with the more pressor
angiotensin II. Renin substrate "reactivity", an arbitrary index
derived from adding a fixed amount of purified human renin
to plasma, also did not vary with changes in sodium balance
but it did vary directly with the absolute substrate concentration.
In normal subjects the mean reaction velocity was 59 x l0 ng/
ml/hr/GU renin and this ranged fiom 35 to 89 ng/ml/hr/GU.
These observations are in keeping with first order kinetics in
which both enzyme and substrate concentrations are rate limiting.
However, the study demonstrates that physiologically, changes
in substrate concentration are not normally determinants of the
rate of angiotensin generation since there was no relationship be-
tween substrate concentration and the endogenous level of plasma
renin activity. Systemic arterio-venous differences in plasma
renin were not observed. However, in 43 patients with benign
essential hypertension, net and fairly equal secretion of renin by
the two kidneys was demonstrated. Mean renal vein renin
activity exceeded arterial levels by 0.48 ng/ml/hr when the mean
arterial renin activity was 1.62 ng/ml/hr.
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Le système de Ia rénine: Variations chez l'homme mesurées
par méthodes radioimmunologiques ou biologiques. Les valeurs
normales de l'activité refine plasmatique (PRA) ont été établies
chez 52 sujets normaux dans Ia gamme des variations phy-
siologiques dues a des modifications ou bilan du sodium. Un
procédé commun l'incubation a été utilisé, suivi soit d'un test
vasopresseur biologique soit du dosage radioimmunologique de
l'angiotensine I. Une interconversion des résultats obtenus par
les deux mCthodes a Cté rendue possible a l'aide d'un facteur
de correction base sur l'activité pressive plus basse de l'angio-
tensine I. La PRA est en relation constante avec Ic debit urinaire
quotidien de sodium. Les valeurs ont vane de 0.5 a 2.8 ng/ml/hre
lorsque l'excrétion du sodium était supérieure a 150 mEq/jour,
de 1.4 6.3 ng/ml/hre lorsque l'excrétion du sodium était entre
50 et 150 mEqjjour et jusqu'à 2! ng/ml/hre lorsque l'excrétion
du sodium était inférieure a 50 mEq/jour. Cependant une
indication plus precise a été obtenue en se servant des limites
inscrites par Ia totalité de Ia courbe sous forme de nomogramme.
Le substrat plasmatique de Ia rénine n'a pas vane lors de change-
ments du bilan de sodium. Sa concentration mesurée par méthode
radioimmunologique a vane de 900 a 2200 ng/ml mais les
variations individuelles étaient faibles. Ces valeurs sont considé-
rablement plus élevées mais plus prés des valeurs réelles que
celles préalablement rapportées qui, de facon erronnée, corn-
paraient l'angiotensine I formée durant l'incubation avec
l'angiotensine II dont I'activité pressive est supérieure. La
<<réactivité>> du substrat de Ia rénine (indication arbitraire
obtenue par l'addition au plasma d'une quantité fixe de rénine
humaine purifiée) n'a pas non plus vane avec les changements
du bilan de sodium, mais a vane directement avec Ia con-
centration absolue du substat. La vélocité moyenne de Ia
reaction était de 59 x iO ng/ml/hre/GU réninc et cette dernière
a vane de 35 a 89 nl/ml/hre/GU rénine alors que Ics concen-
trations du substrat ont augmenté de 1000 a 2200 n/mI. Ces
observations sont compatibles avec one cinétique du premier
ordre de laquelle a Ia fois Ia concentration de l'enzyme et celle
du substrat limitent Ia vitesse de Ia reaction. Toutefois, cette
étude montre qu'à l'état physiologique les modifications de Ia
concentration du substrat ne sont pas les determinants de Ia
vitesse de formation de l'angiotensine. En effet, il n'y a pas de
relation apparcnte entre Ia concentration du substrat et Ic
niveau de Ia PRA. Aucune difference artérioveineuse systémique
de rénine plasmatique n'a été observée. Toutefois, chez 43
patients atteints d'hypertension essentielle benign, one secretion
nette, et pratiquement symétnique, de rénine pas les deux reins
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a été observée. La PRA moyenne de Ia veine rénale a dépassé
les valeurs artérielles de 0.48 ng/ml/hre lorsque Ia concentration
artérielle moyenne de PRA était de 1.62 ng/mI/hre.
In the past decade the development of methods for
the estimation of plasma renin by bioassay [1—6] has
been an important factor enabling further understand-
ing of the physiologic behavior of the hormone [7, 8].
While these various bioassay methods differ con-
siderably in approaches used and in the absolute num-
bers developed, in general, in a wide variety of normal
and physiologic circumstances, there has been sur-
prisingly good agreement with respect to directional
changes observed. Nonetheless, because of the diver-
sity in units of quantitation, many investigators have
expressed the need for more standardization.
More recently, methods for estimation of plasma
renin activity have been introduced in which, after
similar preparative incubation procedures, plasma
renin activity is quantitated by a radioimmunoassay of
angiotensin I, instead of bioassay of angiotensin II
[9—1 3]. This newer approach provides the advantage of
greater sensitivity and also permits the processing of
larger numbers of samples. Such radioimmunoassay
procedures have produced still different, usually
higher, values for renin activity [13]. However, con-
trary to expectations, it has not yet been possible to
demonstrate any consistant relationship between the
values obtained by bioassay and immunoassay [10,
14]. A second problem of the radioimmunoassay
technique relates to the non-specificity of certain anglo-
tensin I antibodies [10, 15]. The use of such antibodies
with a high non-specific blank introduces a technical
hardship and may also be a factor in several reports
which describe surprisingly high concentrations of
circulating and renal venous angiotensin 1 [16, 17].
Accordingly, the physiological meaning of these values
remains unsettled.
In the present study a rational basis has been de-
veloped for interchangeability of the results obtained
by bioassay and immunoassay methods. Also the
problem of the high values for angiotensin I reported
in previous studies appears to have been resolved by
the use of highly specific antibodies.
Using this dual method approach, the physiological
variations in plasma renin activity have been described
over a wide range of changes in sodium intake. Fur-
ther more, new normal values have been similarly
defined for plasma renin substrate concentration and
for substrate "reactivity". The latter index represents
the amount of angiotensin generated when a fixed
amount of highly purified renin is added to the plasma
sample [3].
In addition, in 43 patients with benign essential
hypertension an analysis of renal and peripheral
arteriovenous differences in plasma renin provides a
basis for estimation of the appropriate levels of renal
venous renin required for various levels of peripheral
plasma renin activity.
Methods
Subject material. Thirty-four normal volunteers aged
20 to 40 were maintained on constant normal (100
mEq/day), low (10 mEq/day), or high (200 mEq/day)
dietary sodium intakes for five day periods. Blood was
collected for measurement of renin, renin substrate,
and substrate reactivity on the fifth day of each dietary
period. Random blood samples were also drawn in 18
additional normal subjects on unrestricted diets.
Forty-three patients with benign essential hyperten-
sion and 11 patients with suspected renal hypertension
who were undergoing diagnostic arteriography were
studied. Bloods were drawn from both renal veins, the
vena cava (below the level of the renal veins) and the
aorta for estimation of renin secretion and arteriove-
nous differences in plasma renin activity. These samples
were collected while the patients were maintained on a
normal sodium intake during their admission to the
metabolic unit of the Presbyterian Hospital.
Solutions and materials. 1) 0.1 M Tris buffer: pH 7.5
(Trizma® base, Sigma Chemical Co.), containing
0.3 % bovine serum albumin (Fraction V, Pentex),
0.3 % lysozyme (3 times crystallized, General Bioche-
micals), 0.1 m'i phenylmercuric acetate, and 0.2%
neomycin sulphate. The pH is adjusted to 7.5 with
acetic acid and the buffer is filtered twice before use.
Unless stated otherwise, this Tris buffer is used as
diluant throughout the radioimmunoassay procedure.
2) Antibody: Stored undiluted at —20° C. Before use,
it is diluted I : 100 in Iris buffer.
3a) Asp- I-ileu-5-angiotensin I (Schwartz-Mann):
This product, as supplied by the manufacturer, is not
100% pure. However, the purity of each batch is clearly
labeled and this should be taken into account in the
preparation of standard solutions. Angiotensin I is
stored as 50 jig/mI solution in boiled, distilled water
containing 0.2% neomycin sulphate. Each month a
10 jig/mI solution is prepared in standard Tris buffer
solution, pH 7.5, and on the day of radioimmunoassay
an aliquot is thawed and diluted appropriately in Tris
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buffer. Both the 50 and 10 tg/ml solutions are stored
at —20° C. The more dilute samples are discarded.
3b) Asn-1-val-5-angiotensin II (Ciba): Prepared and
stored as for angiotensin I. This is also not 100% pure
and the solutions should be adjusted according to the
specifications of the manufacturer.
4) Solutions for labeling procedure: i) 0.5 M Phos-
phate buffer, pH 7.5; ii) chioramine T 3.6 mg/mi in
0.05 M phosphate buffer, pH 7.5; iii) sodium metabi-
suiphite, 2.4 mg/mi in 0.05 M phosphate buffer, pH
7.5; iv) angiotensin I, 1 mg/mi, in 0.05 M phosphate
buffer; v) 125NaI 3 mCi (Union Carbide), carrier-free.
5) Columns for iodination purification: G 10 Sepha-
dex (30 x 1.5 cm), Tris buffer pH 7.5; U 25 F Sephadex
(30 x 1.5 cm), Tris buffer pH 7.5; G 25 F Sephadex
(60 x 2.0 cm), 0.5 M formic acid, pH 2.3; G 25 F
Sephadex (60 x 2.0 cm), Tris buffer pH 7.5.
6) 1251-angiotensin I: Stored in 200 p.1 aliquots at
pH 7.5 in Tris buffer at —20° C. Each aliquot is
thawed once and the unused portion is discarded.
7) Antibody/1251 angiotensin mixture: 150,000 cpm
1251-angiotensin (approximately 25 p.1), 0.05 ml anti-
body 41' 203 (1: 100 dilution) in 100 ml Tris buffer.
Final concentration of antibody is 1:200,000.
8) Dextran-coated charcoal. 2 g charcoal (Carbon
Decolorizing neutral, Norit, Fisher Scientific) and
0.2 g dextran (T 70 Pharmacia) in 100 ml water.
9) DFP: (Diisopropyl fluorophosphate) 1/20 dilu.
tion is isopropyl alcohol.
10) Neomycin Sulphate: Upjohn Company.
11) EDTA: 20 ml Vacutainers. Becton Dickinson
4!' 4794 containing 0.17 ml of 15% potassium EDTA.
12) Test tubes: For incubation and radioimmuno-
assay, 12 x 75mm polyethylene (Falcon Plastics 41' 2052).
13) Diluter: Automated Pipeting Station (Micro-
medic Model 41' 24000).
14) Gamma counter: Packard Instruments Models
* 3002 or 4!' 578.
15) Eppe,ØorfPipets: (Brinkmann).
16) Selectapette: (Clay Adams).
Collection of blood. Blood, from subjects in the up-
right position for four hours, is collected into 20 ml
EDTA Vacutainers. The tubes are inverted and chilled
immediately. The blood or plasma is never allowed to
come to room temperature after this time. After centri-
fugation for 20 mm at 4° C the plasma is separated
and stored at — 20° C until incubation for plasma renin
activity.
Renin incubation for bioassay (Table 1). As described
in earlier methods [6], the plasma is thawed quickly in
I. Incubation for plasma renin activity.
1 ml plasma containing 0.003 M EDTA.
0.02 ml 10% neomycin sulfate.
One drop DFP (1/20 dilution in isopropyl alcohol).
0.5 N HCL to pH 5.7.
3 hrs incubation at 37° C (radioimmunoassay)
or
24 hrs incubation at 37° C (bioassay).
Freeze.
Assay.
II. Incubation for renin substrate.
20 .tl plasma.
400 sI human renin: 0.034 GU/ml in 0.1 M phosphate
buffer, pH 5.7, containing 0.003 M EDTA and
200 mg/lOO ml neomycin.
One drop DFP (1/20 dilution).
Incubate 1 hour at 37° C.
Freeze.
Assay 10 and 20 il at 1: 10 dilution.
III. Incubation for substrate reactivity.
0.9 ml plasma containing 0.003 M EDTA.
0.1 ml human renin 0.0085 GU/mi in 0.1 M phosphate
buffer, pH 5.7.
One drop DFP.
Incubate two his at 37° C.
Freeze.
Assay 10 and 20 jil at 1:20 dilution.
front of a fan and all subsequent manipulations before
incubation are carried out in an ice bath at 0° C. After
incubation in a shaker water bath, the samples are
immediately frozen until bioassay.
Renin incubation for radioimmunoassay (Table 1).
This incubation is similar to the bioassay procedure
with the exception that the samples are divided into
three portions before incubation. After rapid chilling,
the samples are stored at —20° C until radioimmuno-
assay. Subdivision of samples avoids multiple freezing
and thawing which tends to cause an increase in the
angiotensin concentration. This may be due to a re-
duced but measurable renin activity.
Incubation for renin substrate (Table 1). The method
for measurement of renin substrate is similar to a
previous method [18]. Sufficient renin is present in the
incubation medium to completely exhaust the substrate
because the values did not increase with more pro-
longed incubation.
Incubation for substrate reactivity (Table 1). The
amount of renin added is sufficient to generate about
Table 1
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50 ng of angiotensin I/mi/hr. In the calculation of
substrate reactivity the endogenous plasma renin activ-
ity is subtracted in order to determine the amount of
angiotensin generated by the added renin.
Bioassay. The angiotensin generated is measured by
injection of the sample into the jugular vein of a 200 g
female rat under pentobarbital anaesthesia and in-
jected with pentolinium. The blood pressure response
is compared with that of known standards of angio-
tensin II utilizing a bracketed assay procedure. Details
of this assay have been reported previously [3].
Angiotensin I radioimmunoassay. 1) Principles of
radioirnmunoassay [19] 1251-angiotensin I combines
with specific antibodies to angiotensin I to form an
antibody antigen complex. For radioimmunoassay, the
amount of antibody in solution is adjusted so that
50% of added 1251-angiotensin I binds to antibody
(bound) and 50% remains unbound (free). Unlabeled
angiotensin added to the solution is able to displace
the bound 1251-angiotensin I so that free 1251-angiotensin
in solution increases. Free angiotensin is removed
from solution by adsorption onto dextran-coated char-
coal and the radioactivity in the supernatant (bound)
counted. The reduction in the bound 1251-angiotensin I
is a measure of the unlabeled angiotensin added to the
solution. A series of tubes is prepared to which known
different amounts of standard angiotension are added
in the presence of fixed amounts of 1251-angiotensin I
and antibody. The percent bound in each tube is
plotted against the amounts of angiotensin added to
each tube (standard curve). The reduction in the per-
cent bound of an unknown sample is then compared
with the standard curve and the angiotensin in the
sample is estimated.
2) Antibody formation: Antibodies to angiotensin I
were generated in rabbits by injection of asp-l-ileu-5-
angiotensin I which was conjugated to homologous
rabbit serum albumin by the carbodiimide condensa-
tion reaction [20]. Rabbits were injected at intervals of
two weeks for 10 weeks and then serum was tested for
titer, specificity, and affinity for angiotensin 1. In-
jections were continued for a further four months at
monthly intervals. Many animals developed highly
specific antibodies by six months. A more detailed
description of the injection procedures is described in
the paper by Gocke et al. [21].
The sera were divided into one ml aliquots and
stored at —20° C in several different freezers. For
radioimmunoassay, a stock solution of the serum is
prepared at 1: 100 dilution with 0.1 M Tris buffer, pH
7.5. It has been stored at this dilution for up to nine
months without loss of activity. The final dilution in
the radioimmunoassay is 1:200,000.
3) lodination of angiotensin I: 1251-angiotensin I is
prepared according to the method of Gocke et al. [21]
with the modification that 0.5 ml of plasma instead of
Tris buffer is added at the end of the labeling proce-
dure. The purification involves binding of the angio-
tensin to specific antibodies and four Sephadex co-
lumns. This results in a very pure, stable preparation
of high specific activity (approximately 500 pCi/jig).
The specificity and purity of each batch is checked by
adding increasing counts (and thus increasing angio-
tensin I) to a series of tubes as illustrated in Fig. 4 of
the report of Gocke et al. [21]. The resultant curve of
B/F should superimpose the standard curve and the
specific activity should be greater than 400 pCi/pg.
Because Union Carbide prepares 125NaI fresh at the
beginning of each month, the labeling is carried out at
that time in order to achieve the highest possible spe-
cific activity.
4) Radioimmunoassay of angiotensin 1: 0.1 M Tris
buffer, pH 7.5, is used throughout the radioimmuno-
assay procedure. Protein is added to the buffer to pre-
vent adsorption of angiotensin onto plastic test tubes
and to increase the stability of the diluted antibody.
Considerable adsorption to plastic has been observed
when the protein concentration is reduced below 400
mg/ 100 ml. Neomycin and phenylmercuric acetate are
added to retard bacterial growth.
Antibody and 1251-angiotensin I are combined prior
to radioimmunoassay. Because storage of this solution
causes reduced sensitivity, the mixture is prepared imme-
diately prior to addition of samples. Two ml of angio-
tensin 1(3000 cpm) are added to each tube. In prelimi-
nary experiments with each fresh label, a series of stan-
dard curves are set up with various amounts of antibody
and label so that the best possible combination for a
sensitive standard curve can be determined. The rela-
tionship of counts to antibody is adjusted so that there
is a fall of at least 5% in the counts bound when ten pg
of angiotensin I is added. It is important that antibody
is not present in too high concentration because if
incomplete saturation of the binding sites occurs,
addition of unlabeled angiotensin leads to little dis-
placement of '251-angiotensin I from the antibody.
Standard angiotensin I is diluted to four different
concentrations. Unknown samples are also prediluted
to 1:5, 1:25, or 1:100 if the values are expected to be
above the normal range for a normal sodium intake.
All dilutions are in Tris buffer. Ten and 20 p1 of stand-
244 Sealey et al.
ards or unknown samples are added to two ml of
antibody/1251-angiotensin mixture in plastic test tubes,
thereby assaying two different concentrations of each
unknown. Standards are assayed at each concentration
in duplicate. The unlabeled angiotensin in the standard
curve ranges from ten to 400 pg. In addition, two pairs
of duplicates are prepared to which neither antibody
nor sample is added. These are for measurement of the
non-specific binding of '251-angiotensin to protein in
the buffer solution, and also the total counts added
to each tube. A third pair is set up with both antibody
and 1251-angiotensin but no added sample or standard
angiotensin. This last pair determines the zero point
on the standard curve. All tubes are mixed, then in-
cubated at 4° C for 24 hours.
Dextran-coated charcoal (0.5 ml) is added to each
tube, except the pair set up for determination of the
total counts. The addition of charcoal is carried out as
quickly as possible. A magnetic stirrer is used to ensure
adequate stirring. Because of the tendency of charcoal
to remove a small amount of bound angiotensin from
the antibody, the standard curve is split so that the
charcoal is added to one-half of the duplicates at the
beginning and to the other half at the end of the set.
Thus, variability in the time of exposure of the samples
to charcoal is reduced. Tubes are mixed for three sec
on a Vortex mixer and then centrifuged together for
20 mm at 4° C and 4000 RPM. The supernatant, which
represents the bound fraction, is counted for ten mm
in a well-type gamma counter.
5) Radioimmunoassay of samples with low plasma
renin activity: It is necessary to add more than 20 tl
of these samples to the incubation medium. Because the
increased volume of the incubation medium affects the
final result, and because the presence of plasma in high
concentration tends to reduce somewhat the affinity of
the antibody, the incubation medium is adjusted so
that each tube including the standard curve, contains
5 % plasma. The plasma which is added as, a diluant is
pooled plasma, treated with charcoal to remove endo-
genous angiotensin I.
6) Calculation of results: The relationship of bound
to free is calculated using a logit analysis [22]. This is
convenient because the plot forms a straight line.
B/T
BØ/T
B = bound counts for each standard or sample
B0= bound counts for zero point of the curve
T = total counts added to each tube
logit Y=2.303 log10
In practice, only is calculated and plotted
against the dose of angiotensin on log/log paper. Be-
cause of this log/log plot, the standard curve is set up
so the standards approximately double at each conse-
cutive point on the curve.
7) Quality control: For continuous checks of the
accuracy and reproducability of the radioimmuno-
assay, two standard plasma samples are routinely ana-
lysed with each set. The dilutions of these standard
samples are such that between them they span the
range of the standard curve. If the result of either
sample is outside 20 % of a previously determined
mean, the whole series is descarded.
The set is discarded if the non-specific binding rises
above 8 % of the total counts. Sometimes the duplicates
of the non-specific binding do not check. We consider
this to be due to variability in the addition of the
charcoal and the set is discarded. If duplicates of in-
dividual samples vary by greater than 20% of the
mean value, the sample is repeated. Both duplicates
must fall on the standard curve before the result is
accepted.
Results
Bioassay and radioimmunoassay of plasma renin
activity.
a) Reproducibility of bioassay and radioimmuno-
assay. The mean plasma renin activity of the same
sample assayed 31 times by bioassay in 31 different sets
incubated on different days over a period of one year
was 1.68 SD 0.37 ng angiotensin I/mi/hr.
The plasma renin activity of four different plasma
samples was analysed repeatedly by radioimmuno-
assay (Table 2). The mean standard deviation of these
assays was 11.8%.
b) Bioassay: Comparison of results using angiotensin
I or angiotensin II standard. When angiotensin II was
compared with angiotensin I in the bioassay using a
bracketed assay, the activity of angiotensin II was 1.7
times that of angiotensin I when equal weights were
compared. This difference is due in part to the 1.25
times higher molecular wt of angiotensin I. However,
this does not completely account for the difference.
Angiotensin I may be partially destroyed by angioten-
sinases before conversion to angiotensin II.
The greater potency of angiotensin II was confirmed
in the analysis of samples which were analysed by bio-
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c) Comparison of radio immunoassay and bioassay
using angiotensin I standards. Radioimmunoassay re-
suits of 70 samples were compared to bioasay results
of the same samples using an angiotensin I standard
(Fig. 2). The radioimmunoassay results were 1.2 times
higher than the bioassay results. However, the corre-
lation was highly significant (P<0.OOl). The difference
may have been due to the longer time of incubation
utilized for the bioassay procedure. The results derived
Bioassay of plasma renin activity
Comparison of results using angiotensin I or
angiotensin II standards
Incubation time: =24 hrs
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0
PRA (angio I) (ng/ml/hr)
Fig. 1. Bioassay of plasma renin activity. Results using angio-
tensin II as standard in the bioassay are compared to results of
same samples assayed against an angiotensin I standard. The
ratio of the potency of angiotensin I and II standards is shown,
but the data are not presented in the figures.
2.0 3.0 4.0 5.0 6.0 7.0
Radioimmunoassay (angio I) PRA (ng/ml/hr)
Fig. 2. Bioassay of plasma renin activity compared to radio-
immunoassay of same samples. Angiotensin I was used as stand-
ard in both assays.
from radioimmunoassay may be higher because of
utilization of less substrate during the incubation pe-
riod. This possibility is supported by the observation
that the samples with the highest renin exhibit the
greatest discrepancy (Fig. 2). It is generally assumed
that if less than 10% of the substrate is consumed
during the incubation period, the reaction velocity is
constant [23]. At substrate concentrations of 1500
ng1ml, 10% of the substrate will be consumed during
the 24-hour incubation necessary for bioassay when
the plasma renin activity is 6.3 ng/ml/hr. However,
during the 3-hour incubation for radioimmunoassay,
10% substrate will be utilized when the plasma renin
activity is 50 ng/ml/hr.
Thus in order to evaluate precisely those samples
with very high plasma renin activities, such as the
difference between renal vein activities in patients with
renal artery stenosis, a shorter incubation time is
essential. Table 3 presents data from such a patient.
It can be calculated that during the three hour in-
cubation the substrate was actually exhausted in the
sample drawn from the left renal vein. If the sample had
been incubated for 24 hours, as for the bioassay pro-
cedure, no difference would have been apparent in the
plasma renin activity from the two renal veins.
d) Comparison of bioassay (angiotensin II standard)
and radioitnmunoassay (angiotensin I standard) — Rou-
tine procedures. Because routinely the bioassay uses
Table 2. Reproducibility of bioassay
and radioimmunoassay
Plasma renin activity
Comparison of bioassay (angio I std.)
with radioimmunoassay (angio I std.)
Incubation time:
Bio=24hrs
RIO=3hrs
Mean PRA SD SE N
ng/ml/hr
Bioassay
1.68 0.37 0.07 31
Radioimmunoassay
1.26 0.24 0.06 16
2.56 0.26 0.06 17
4.85 0.42 0.13 11
8.69 1.13 0.29 15
. .
RIO Angiol 1 2
Bio Angio I .
3.0
2.0
S
1.0
S
I I Iassay using angiotensin I rather than angiotensin II as
a standard in the bioassay procedure (Fig. 1). Although
a statistically significant relationship exists between the
assays using the two different standards (P<0.001) the
ratio of the results is 1.9, not unlike the ratio of the
standards when they are assayed against each other
(1.7).
0
1.0
4.0
-. 6.0
2.0
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Table 3. Radioimmunoassay of samples
with very high PRA
Sample Plasma renin activity Renin
substrate
3hr 10mm
incubation incubation
ng/m1/hr ng/m1/hr ng/mt
Right renal vein 147 228 1278
Left renal vein 492 1839 1236
Venacava 122 225 1300
Aorta 173 252 1358
angiotensin II as standard and the radioimmunoassay
utilizes angiotensin I, it was necessary to correlate the
two assays in order to compare results. Fig. 3 presents
data from 95 duplicate determinations. The results by
radioimmunoassay are 2.2 times higher than those
determined by bioassay. However, the correlation is
highly significant (P.<0.001). A similar relationship
between the two assays can be calculated from the data
which demonstrate that the ratio of the bioassays using
angiotensin I or II standards is 1.87, and the ratio of
the three hour to the 24-hour incubation is 1.2. Multi-
plication results in a ratio of 2.24.
e) Recovery of added angiotensin I. Angiotensin Tin
amounts ranging from 50 to 200 pg was added to
plasma. Both the endogenous and total angiotensin in
these samples were measured by radioimmunoassay.
The recovery of exogenous angiotensin was l05±sD
32%. When one to five ng of angiotensin I was added
to plasma which was then incubated for three hours
the recovery was 99±sD 24%. Because these sets of
recoveries are the result of two analyses, the variability
Plasma renin activity
Correlation of bioassay (anglo II std)
and radioimmunoassay (angio I std)
6.0 Incubation time:
lOOpg 200pg
Angiotensin I
Fig. 4. Cross reactivity of angiotensin I antibody. (.) asp-i-lIeu-
5-angiotensin I; (y) asp-arg-val-tyr, 8 ng; (0) Hog substrate,
3000 ng; () Ileu-his-pro-phe, 13 ng; (A) Angiotensin II, lOng;
(•) asp-arg-val-tyr-ileu-his-pro, 12 ng; (A) arg-val-tyr-ileu-his-
pro-phe, 11 ng; (0) tetradecapeptide, 25 ng; (v) tyr-ileu-his-
pro-phe, 12 ng.
is greater than that found in the measurement of
plasma renin activity by this method.
•f) Cross-reactivity of angiotensin I-antibody 203.
Neither angiotensin II, nor any of the fragments of
angiotensin II which were tested, nor hog substrate,
nor the tetradecapeptide cross-reacted with the anti-
body to any significant extent (Fig. 4).
g) Effect of neomycin and DFP on PRA. Neomycin
was omitted from the incubation medium in three
different assays and the plasma renin activity was
reduced from a mean of 7.5 to 5.9 ng/ml/hr during a
one hour incubation. When DFP was omitted, in
three different assays the reduction in plasma renin
activity was 50%. The mean plasma renin was reduced
from 11.7 to 5.8 ng/ml/hr in only a one hour incuba-
tion. These data reemphasize the necessity for both
bacteriostatic agents and angiotensinase inhibitors
even during short incubation periods.
Cross reactivity
of angiotensin I antibody 4l 203
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Fig. 3. Correlation of routine bioassay procedure (angiotensin II
standard) and radioimmunoassay (angiotensin I standard).
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Relationship of plasma renin activity
to sodium excretion un normal subjects
52 subjects
• Bioassay x2.2, 56 determinations
o Radioimmunoassay, 55 determinations
Table 4. PRA, renin substrate and substrate reactivity
in normal subjects
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Fig. 5. Relationship between plasma renin activity and urinary
sodium excretion. Combination of results derived from bioassay
and radioimmunoassay.
h) Converting enzyme inhibition. Angiotensin 11
generated during a three hour incubation was measured
in six samples by radioimmunoassay [21]. The plasma
renin activity ranged from 3.0 to 222 ng angiotensin
I/ml/3 hours. Angiotensin II in these samples ranged
from 0.10 to 0.60 ng/ml/3 hrs. Thus, less than 2 % of
the angiotensin I formed during the incubation was
converted to angiotensin II.
Normal values for plasma renin activity (Fig. 5).
Normal values for plasma renin activity ranged from
0.5 to 2.8 ng/ml/hr when urinary sodium excretion was
above 150 mEq/day, from 1.4 to 6.3 ng/ml/hr when
urinary sodium excretion was between 50 and 150
mEq/day, and up to 21 ng/mI/hr when urinary sodium
was below 50 mEq/day. A continuous dynamic re-
lationship was described between plasma renin activ-
ity and urinary sodium excretion as illustrated on
Fig. 5.
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Relationship between renin substrate and substrate reactivity
19 normal subjects
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Fig. 6. Relationship between renin substrate concentration and
renin substrate reactivity in 19 normal subjects.
Fig. 7. Comparison of arterial and either renal venous or peripheral venous plasma renin activity PRA. Samples were collected simul-
taneously from the aorta, from the vena cava below the level of the renal veins, and from the renal veins. The data are plotted
on a logarithmic scale for clarity. The lines of correlation are plotted in the insert on a linear scale. The line for arterial vs.
peripheral venous PRA falls just slightly above the line of equality whereas the Inc for renal venous PRA is clearly lower than the
line of equality.
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Normal values for renin substrate concentration (T4ble
4, Fig. 6).
The normal range of renin substrate when measured
by radioimmunoassay was from 900 to 2200 ng/ml,
but the variation in any one subject was quite small.
There was no consistant relationship between sodium
intake and renin substrate concentration.
Normal values for substrate reactivity (Table 4, Fig. 6).
These results, derived from radioimmunoassay data,
show no relationship to dietary sodium intake. How-
ever, there is a direct relationship between substrate
reactivity and renin substrate concentration which is
highly significant (P .< 0.001). The mean reaction veloc-
ity was 59 x l0 ng/ml/hr/GU of renin and this ranged
from 35 to 89 at substrate concentrations from 1000
to 2200 ng/ml.
When Subjects 16 and 18 are compared in Table 4,
it is apparent that there can be a wide variation in both
substrate concentration and substrate reactivity be-
tween subjects. Throughout the group, there was no
consistant relationship between substrate concentra-
tion and the level of plasma renin activity at a partic-
ular sodium intake. Thus dynamic changes in renin
/
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concentration alone appear to determine the amount
of angiotensin generated and not dynamic changes in
substrate concentration.
Comparison of arterial and venous samples.
The results of 71 determinations of the plasma renin
activity in aortic and vena caval samples are shown in
Fig. 7.
The mean plasma renin activity in the arterial sample
is 1.06 times that of the venous sample, but this
difference is not significant. However, the correlation
of the plasma renin activity in the two samples is
highly significant (P<0.00l). Thus, in assessing renal
secretion of renin, little is to be gained by the collection
of an arterial sample because the plasma renin activity
in the artery can be substituted by that found in the
vena cava.
In addition to peripheral venous and arterial sam-
ples, blood was collected from both renal veins in 43
patients with benign essential hypertension. The mean
renal venous plasma renin activity was 2.10 ng/ml/hour
and the arterial plasma renin activity was 1.62 ng/ml/hr
(P<0.0l) (Fig. 7). Thus, the mean increment, across
the kidneys in these patients was approximately 30%.
This relationship was apparent over a range of plasma
renin activity from 0.2 to 9 ng/ml/hr.
Endogenous angiotensin I in samples collected for PRA.
Angiotensin I was determined in the plasma of 187
unincubated samples in which plasma renin activity
Table 5. Comparison of PRA and angiotensin I levels in renal venous samples from hypertensive patients
Patient Plasma renin activity
and angiotensin I concentration
Diagnosis Therapy Cure?
LRV RRV Artery Vein
I a 0.6 0.6 0.5 EHT
b <0.1 <0.1 <0.1
2 4.7 4.9 3.7 3.0 EHT; Ccr=81
<0.1 0.17 <0.1 <0.1
3 17.4 7.4 6.0 75a MTH, shrunken left kidney. Ccr25
0.34 <0.1 <0.1
4 32.0 22.0 21.0 27.0 MHT, bilateral kidney disease. Ccr=55
1.2 1.9 0.9 0.9
5 2.7 2.7 1.2 1.4 Normotensive; It. kidney mid-renal infarct.
<0.1 <0.1 <0.1 <0.1
6 3.3 3.6 3.9 2.7 Bilat. kidney disease. Ccr=r36
<0.1 <0.1 <0.1 <0.1
7 0.5 2.2 0.3 0.5b Bilat. kidney disease. Shrunken rt. kidney.
0.12 <0.1 <0.1 <0.1 Ccr=45
8 19.0 15.0 12.0 10.Oa Lt. RAS Nephrex No cure
0.25 <0.1 0.12 <0.1
9 16.0 33.0 16.0 10.Ob Rt. kidney Nephrex Cured
0.39 <0.1 <0.1 <0.1 infarction
10 13.5 8.4 6.4 6.7a Lt. RAS Nephrex Improved
0.44 <0.2 0.28 <0.2
11 4.4 20.0 3.6a Rt. RAS Vascular Cured
<0.1 0.71 <0.1 Repair
Abbreviations: a=Plasma renin activity, ngjml/hr; b=Plasma angiotensin 1;
hypertension; RAS= renal artery stenosis; Ccr= creatinine clearance.
a renin and angiotensin I equally good indicator for predicting affected kidney.
b renin a better indicator for predicting affected kidney.
EHT= essential hypertension; MHT= malignant
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was also measured. There was a highly significant
relationship between the two measurements (P<0.00l).
However, the average endogenous angiotensin I in
unincubated samples was only 0.8 % of the angiotensin
I generated during the three hour incubation. Since.
this value is low when compared with the amount of
angiotensin generated during the incubation these de-
terminations are not carried out routinely. Values for
endogenous angiotensin I in the normal range of
plasma renin activity ranged from undetectable to
300 pg/mi with a mean of about 30 pg/mI. Since no
renin inhibitor is added to plasma and since the con-
version of angiotensin I to II is blocked by EDTA, it
is unlikely that these values, although lower than pre-
viously reported [15, 16], reflect the true level of endo-
genous angiotensin I.
Endogenous angiotensin I was also measured in
renal vein, vena caval, and arterial samples from 11
patients with suspected renovascular hypertension.
Seven of these patients had either unilateral renal
artery stenosis or a shrunken kidney (Table 5). One
patient (No. 5) was normotensive and had slightly
elevated PRA from both kidneys. Renin from the
affected kidney in the remaining six patients was
consistently elevated whereas the angiotensin I level
was elevated in only four of the six. There was therefore
no indication that this measurement was a better
indication of the affected kidney than the measurement
of plasma renin activity.
Discussion
This report describes rapid and accurate bioassay
and radioinimunoassay me'thods for the measurement
of plasma renin activity, renin substrate concentration
and substrate reactivity. All methods for measurement
of renin developed to date utilize the fact that renin
reacts with a plasma alpha-2-globulin to form the
decapeptide angiotensin I [1—6, 9—13], Pressor bioassay
methods for quantitation of angiotensin I are possible
since the enzymes of the assay rat hydrolyze angioten-
sin I into the pressor peptide angiotensin II by re-
moving the terminal histidyl-leucine [241. The angio-
tensin TI thus formed is quantitated by comparing the
pressor response of the unknown sample with that of
standards of angiotensin II [1—6]. Alternatively, the
angiotensin I generated during incubation can be
quantitated by radioimmunoassay utilizing specific
antibodies to angiotensin I [9—13]. In either case,
plasma renin activity is expressed by the rate of angio-
tensin generation.
Angiotensinases in plasma must be inactivated to
prevent destruction of the angiotensin formed during
incubation. Methods developed for dealing with this
problem include the chemical separation of renin [1],
adsorption of the formed angiotensin onto a resin [2],
dialysis [3—5], inactivation by heat at pH 4.5 [5] and
the addition of inhibitors [3, 4, 6]. The present method
reaffirms that angiotensinase activity can be completely
inhibited at pH 5.7 by addition of EDTA and DFP [6]
without the need for dialysis [3]. The pH optimum of
5.7 is utilized for the incubation. Some other renin
methods have elected to use instead a pH of 7.4 for
incubation on the basis that it is more physiological.
However, this approach reduces sensitivity consider-
ably and has the technical disadvantage that at 7.4
small fluctuations in pH induce relatively large changes
in renin activity.
Converting enzymes in plasma must also be com-
pletely inactivated for measurement of angiotensin I
by radioimmunoassay. EDTA is a potent inactivator
of converting enzyme [24]. However, Haber et al. have
reported that during a 24 hour incubation, EDTA alone
permits 100% destruction of angiotensin I [10]. This
lack of effectiveness of EDTA may be due in part to
their selection of pH 7.4 for incubation, which is the
pH optimum for converting enzyme activity. The
present method takes advantage of the fact that con-
verting enzyme activity is considerably reduced at pH
5.7 [24]. The almost complete inhibition of converting
enzyme activity at this pH in the presence of EDTA
could not be attributed to the action of DFP since this
substance has no inhibitory action on converting en-
zyme activity [25]. However, DFP is essential to inhibit
angiotensinase activity. Cohen et al. [13] demonstrated
excellent recovery of added angiotensin Tin the presence
of EDTA alone in 30 mm incubation at pH 5.5. How-
ever, DFP is essential for more prolonged incubations.
In the present method, no change in the incubation
medium is necessary for quantitation of angiotensin I
by either radioimmunoassay or bioassay. This may be
a factor in the excellent correlation of the two methods.
It is difficult to explain the higher values for normal
subjects obtained by Cohen et al. [13]. Their values,
from normal subjects at similar sodium intakes, are
twice as high as those reported herein, despite almost
identical incubation procedures. One factor in the
discrepancy may be the lack of purity of commercially
available angiotensin I and angiotensin II. If this is not
taken into consideration as in the present method, the
values could be falsely high. Since the report of Cohen
et a!. [13] does not attempt to explain the differences
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in the values derived from radioimmunoassay and
bioassay, it is not possible to assign a reason for the
discrepancy in the results.
Indeed, most previous studies have failed to correlate
results derived from the same samples measured both
by bioassay and radioimmunoassay [9—12]. Lack of
identity in the bioassay and radioimmunoassay has
been pointed out by Kritzinger, Kanengoni, and Jones
[14]. In the present method, a correction factor has
been developed which is derived from two components.
The first results from the use of angiotensin II instead
of angiotensin I as a standard in the bioassay. Since
incubation results are expressed in terms of weight of
angiotensin generated, rather than on a molar basis,
the bioassay results are falsely low since the molecular
wt of angiotensin I exceeds that of angiotensin II. An
additional and related factor is the consistently greater
pressor potency of an equimolar solution of angioten-
sin II as compared with angiotensin I due to incom-
plete conversion by the assay animal. A second com-
ponent producing lower values in the bioassay derives
from the increased utilization of substrate during the
more prolonged incubations required for a pressor
assay. The discrepancy caused by these two components
can be resolved by a correction factor of 2.2. Thus,
when the results of bioassays are so corrected, both
methods yield identical results over the entire physio-
logical range (Fig. 5).
Unlike several other reported methods [10—12] in the
immunoassay approach described herein, it is not
necessary to subtract a blank from the measurement of
angiotensin I. This halves the number of samples
required for measurement of plasma renin activity. A
possible blank may be derived from two sources: the
first is caused by non-specificity of the antibodies so
that some other substance in plasma may cross-react
with the antibody [10, 12, 14, 15]. The second problem
arises when exogenous renin substrate is added for
measurement of plasma renin concentrations. These
preparations are often contaminated by a small amount
of renin which can lead to an increased generation of
angiotensin during the incubation [11]. In the first
instance, the amount of non-specific "angiotensin" in
each unincubated plasma must be substracted [10, 12].
However, in the second situation, only the amount of
renin in each batch of substrate need be assayed and
subtracted from each determination. However, the use
of two separate assays involves more work and de-
creased accuracy.
Plasma renin activity in normal subjects fluctuates
widely according to the state of sodium balance [7, 8]
as reflected by the daily rate of sodium excretion
during steady state coditions. The description of this
continuous dynamic relationship between renin and
salt balance allows an inherently more precise analysis
of data than the more customary practice of establish-
ing normal ranges related to bracketed ranges of salt
intake. In the latter approach, small increments in
sodium balance included in the range of the brackets
may be associated with considerable differences in
renin activity if the brackets are applied at a level of
sodium intake in which the slope of the hormonal
response is steep.
Unlike the report of Rosset and Veyrat [26], we
have been unable to demonstrate any relationship
between sodium balance and renin substrate concen-
tration (Table 4). However, a direct relationship does
exist between substrate reactivity and the renin sub-
strate concentration (Fig. 6), a finding which reaffirms
the view that in normal human subjects substrate con-
centration is rate-limiting [18, 27]. Amongst normal
subjects, substrate concentration can differ by as much
as two-fold, but intra-individual variation from day to
day is usually small. Despite differences in substrate
concentration between individuals, those with the
highest plasma renin activity at a particular sodium
intake are not those with the highest substrate concen-
tration (Table 4). This is further evidence [18] that
renin secretion tends to "feed back" in subjects with
high substrate levels in order to maintain an appro-
priate rate of angiotensin generation (i. e., renin actvi-
ity).
Therefore, although the enzyme-substrate reaction
obeys first-order kinetics so that substrate concen-
tration is biochemically rate-limiting in vitro, there is
little evidence that physiologically it is a critical
variable in determining the rate of angiotensin pro-
duction. Thus, renin alone appears to be the dynamic
component of the system, the secretion of which adjusts
itself primarily to the demand for angiotensin. The
implication of these observations is that plasma renin
"activity" measurements are usually a reliable index
of the physiological activity of the system. In those
methods which measure renin concentration by the
addition of heterologous substrate {1, 5, 11], it is
necessary to measure substrate concentration as well as
renin in order to assess the capacity of the plasma to
generate angiotensin.
The measurement of substrate reactivity has been
used to investigate the existence of activators or in-
hibitors of renin in plasma [3, 28]. We have developed
no evidence for the existence of such moderators of
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renin activity in the plasma of either normal subjects
or patients with various forms of hypertension since
in every situation studied the substrate reactivity
change was directly related to substrate concentration.
Values for renin substrate concentration in normal
subjects presented in Table 4 are considerably higher
than previously reported values [4, 18, 26, 27]. This is
explained by the use of an angiotensin I standard in the
present radioimmunoassay whereas previously reported
values were derived from a bioassay in which angio-
tensin I was generated during the incubation, but the
reference bioassay standard was angiotensin II. The
present values are therefore likely to be closer to the
true value. Accordingly, values for the Km of renin
substrate which have been reported [27] are probably
an underestimation of the true value.
There is a paucity of information about arterio-
venous differences of plasma renin activity in human
subjects. In the present study, the plasma renin activity
in the artery and peripheral vein was not significantly
different, thus validating the use of venous samples in
physiologic studies (Fig. 7). Hosie et al. have reported
similar data from studies in anesthetized dogs [29]. In
addition, net renal secretion of renin was demonstrated
in 43 patients with benign essential hypertension from
whom renal vein blood was collected. The mean PRA
in the renal vein was 2.10 ng angiotensin/ml/hr, 30%
higher than in arterial samples when the mean arterial
plasma renin activity was 1.62 ng angiotensin/ml/hr.
Thus, it can be deduced that net secretion of renin of
0.48 ng angiotensin/ml from each kidney at presum-
ably normal renal plasma flows can lead to a peripheral
plasma renin activity of 1.62 ng angiotensin/mi/hr.
Recently, there have been reports from two labora-
tories that a better indication of the affected kidney in
Goldblatt hypertension is derived from measurement
of endogenous angiotensin I levels in renal vein sam-
pies [16, 17]. Accordingly, in the present study of 11
patients with possible renovascular disease, there was
no indication that the level of angiotensin Tin the renal
vein was a better indicator of vascular disease than the
level of plasma renin activity (Table 5). In fact, in two
of six studies in which only one kidney was affected,
angiotensin I levels were elevated in the contralateral
kidney. In addition, the mean level of angiotensin I in
the renal veins of these patients, when it was detectable,
was only 0.57 ng/ml. The highest level was 1.9 ng/ml
in a patient with a plasma renin activity of 22 ng
angiotensin/ml/hr of renin from the same vein. It must
be assumed that when angiotensin I is measured spe-
cifically, that is, by using antibodies with a high degree
of specificity, the levels are lower than have been de-
scribed [17] and they do not appear elevated in the vein
from the affected kidney. This impression tends to
question that hypothesis that angiotensin I is generated
intrarenally to a significant extent in the affected
kidneys and secreted into the renal veins at rates in
excess of those which would be expected from the con-
current level of plasma renin activity.
The measurement of plasma renin activity has be-
come a more accurate and high-capacity analytical tool
with the development of radioimmunoassay. However,
the accuracy of this approach is dependent on strict
quality control so that the bioassay procedure provides
a reliable and accurate alternative method which could
be more convenient for many laboratories. The uti-
lization of both of these tools in the present study has
developed criteria for their interchangeability and has
led to the development of a concept of a standard re-
lationship between renal vein renin activity and arterial
or venous levels of plasma renin activity in patients
with uncomplicated hypertension with presumably
normal or nearly normal renal plasma flows. The dy-
namic relationship of plasma renin activity to sodium
balance in normal subjects and the analysis of this
relationship to essential hypertension has already been
extremely fruitful [30]. The approaches and the nomo-
grams described herein can be applied in other labo-
ratories to the study of abnormalities in man by simply
establishing correspondence of obtained results at
separated levels of sodium excretion in normal sub-
jects.
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